CA2925119A1 - Methods and compositions for treating and/or preventing mucositis - Google Patents

Methods and compositions for treating and/or preventing mucositis Download PDF

Info

Publication number
CA2925119A1
CA2925119A1 CA2925119A CA2925119A CA2925119A1 CA 2925119 A1 CA2925119 A1 CA 2925119A1 CA 2925119 A CA2925119 A CA 2925119A CA 2925119 A CA2925119 A CA 2925119A CA 2925119 A1 CA2925119 A1 CA 2925119A1
Authority
CA
Canada
Prior art keywords
chosen
compound
groups
mucositis
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2925119A
Other languages
English (en)
French (fr)
Inventor
John L. Magnani
John M. Peterson
Ingrid G. Winkler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescent Biopharma Inc
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Publication of CA2925119A1 publication Critical patent/CA2925119A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2925119A 2013-09-30 2014-09-29 Methods and compositions for treating and/or preventing mucositis Abandoned CA2925119A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361884856P 2013-09-30 2013-09-30
US61/884,856 2013-09-30
PCT/US2014/057978 WO2015048616A1 (en) 2013-09-30 2014-09-29 Methods and compositions for treating and/or preventing mucositis

Publications (1)

Publication Number Publication Date
CA2925119A1 true CA2925119A1 (en) 2015-04-02

Family

ID=52744558

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2925119A Abandoned CA2925119A1 (en) 2013-09-30 2014-09-29 Methods and compositions for treating and/or preventing mucositis

Country Status (7)

Country Link
US (1) US20170296566A9 (enExample)
EP (1) EP3052510A4 (enExample)
JP (1) JP2016531871A (enExample)
CN (1) CN105683208A (enExample)
AU (1) AU2014324634A1 (enExample)
CA (1) CA2925119A1 (enExample)
WO (1) WO2015048616A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038423T2 (hu) 2012-12-07 2018-10-29 Glycomimetics Inc E-szelektin antagonistákat felhasználó vegyületek, készítmények és eljárások vérképzõ sejtek mobilizációjára
CN107108679B (zh) 2014-12-03 2020-10-23 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
CA3002883A1 (en) * 2015-11-03 2017-05-11 Glycomimetics, Inc. Antibodies for targeting cancer stem cells and treating aggressive cancers
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
US20200316100A1 (en) * 2016-05-24 2020-10-08 GycoMimetics, Inc. Haloalkyl fucose-containing selectin antagonists
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
BR112019006642A2 (pt) 2016-10-07 2019-07-02 Glycomimetics Inc antagonistas multiméricos de e-selectina altamente potentes
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
WO2020123435A2 (en) * 2018-12-10 2020-06-18 Glycomimetics, Inc. Methods of treating hiv and aids and the elimination of latent reservoirs of hiv infection using selectin, galectin, and siglec antagonists
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
MX2022002102A (es) * 2019-08-20 2022-07-04 Glycomimetics Inc Proceso para preparar un intermediario inhibidor de e-selectina.
JP2023529485A (ja) * 2020-06-14 2023-07-10 グリコミメティクス， インコーポレイテッド Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458777B1 (en) * 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
SI2264043T1 (en) * 2005-09-02 2018-01-31 Glycomimetics, Inc. HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS
EP2794626B3 (en) * 2011-12-22 2020-08-05 GlycoMimetics, Inc. E-selectin antagonist compounds
US20160333043A1 (en) * 2014-01-17 2016-11-17 Glycomimetics, Inc. E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose

Also Published As

Publication number Publication date
AU2014324634A1 (en) 2016-04-14
WO2015048616A1 (en) 2015-04-02
US20160243145A1 (en) 2016-08-25
CN105683208A (zh) 2016-06-15
EP3052510A1 (en) 2016-08-10
US20170296566A9 (en) 2017-10-19
JP2016531871A (ja) 2016-10-13
EP3052510A4 (en) 2017-03-29

Similar Documents

Publication Publication Date Title
US20170296566A9 (en) Methods and compositions for treating and/or preventing mucositis
AU2018395417B2 (en) Heterobifunctional inhibitors of E-selectin and galectin-3
DK2794626T3 (en) E-selectin antagonist compounds
CA2968391A1 (en) Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
DK2928476T3 (en) RELATIONSHIPS, COMPOSITIONS AND METHODS OF USING E-SELECTIN ANTAGONISTS FOR MOBILIZATION OF HEMATOPOIETIC CELLS
CA3054605A1 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
US20150284420A1 (en) E-selectin antagonist compounds and methods of use
EP3383882A1 (en) Heterobifunctional pan-selectin antagonists having a triazole linker
US20160333043A1 (en) E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose
WO2016164394A1 (en) 2-halo-galactose-containing selectin antagonists
EP3958978A1 (en) Galactose-linked multimeric glycomimetic inhibitors of e-selectins, galectin-3, and/or cxcr4 chemokine receptors
WO2020219419A1 (en) Multimeric pan–selectin antagonists
WO2009004096A1 (en) New phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same
EP4143200A1 (en) Cd33 ligands suitable for incorporation into carriers
WO2023060021A1 (en) Polar cd33 ligands suitable for incorporation into carriers
WO2012165394A1 (ja) 抗腫瘍剤
US20230167149A1 (en) Cd33 ligands suitable for incorporation into carriers
US20200316100A1 (en) Haloalkyl fucose-containing selectin antagonists
US20240287121A1 (en) Galectin-3 inhibiting c-glycoside oximes
TW202206417A (zh) 利用經修飾的單醣化合物治療癌症的方法
WO2014070988A1 (en) Compounds and methods to enhance the oral availability of glycomimetics
HK1240233A1 (en) Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
HK1240233B (en) Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
NZ732034B2 (en) Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200930